Rhythm Pharma Q1 net revenue $26.0M (+126% YoY); net loss $141.4M on $92.4M LB54640 charge

RHYTHM PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$2.35 revenue$25,967,000

Net product revenue $26.0M (Q1 2023: $11.5M); 74% from U.S. sales.
Net loss $141.4M ($2.35/share) vs $52.2M ($0.92/share) prior year; R&D spend $128.7M incl $92.4M IPR&D for LB54640.
Cash $201M at March 31; closed $150M preferred stock financing April 15 extending runway into 2026.
On track to submit sNDA for IMCIVREE in pediatric patients 2 to <6 years old in Q2 2024.
Phase 3 hypothalamic obesity trial top-line data expected H1 2025; Japanese cohort dosing starts Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

RHYTHM PHARMACEUTICALS, INC. reported for the quarter ended March 31, 2024 results: revenue $26.0 million.

Period: for the quarter ended March 31, 2024
Revenue: $26.0 million
Result: reported results

Exact text from the filing

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

RHYTHM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-057691

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.